Following is one of the patent documents most requested by researchers using CAS electronic products.
|
CAS indexed 462 chemical substances from this document.
CAS subject entries for this document include: Gene, animal; Delta agent; Ribonucleic acids, messenger; and 11 additional concepts. | |
CAPLUS COPYRIGHT 2005 ACS on STN
| TITLE:
| Method and enzymic RNA for inhibiting cancer development |
| INVENTOR(S):
| Thompson, James D.; Draper, Kenneth G. |
| PATENT ASSIGNEE(S):
| Ribozyme Pharmaceuticals, Inc., USA |
| SOURCE:
| PCT Int. Appl., 69 pp. CODEN: PIXXD2 |
| LANGUAGE:
| English |
PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE
--------------- ---- -------- -------------------- --------
WO 9323057 A1 19931125 WO 1993-US4573 19930513
W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 5610052 A 19970311 US 1992-936110 19920826
US 5750390 A 19980512 US 1992-936421 19920826
US 6492512 B1 20021210 US 1992-936532 19920826
AU 9342489 A1 19931213 AU 1993-42489 19930513
AU 687001 B2 19980219
EP 641212 A1 19950308 EP 1993-911311 19930513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 08502950 T2 19960402 JP 1993-500939 19930513
US 5989906 A 19991123 US 1994-192942 19940207
US 6544755 B1 20030408 US 1994-192943 19940207
US 5639655 A 19970617 US 1994-233030 19940425
US 5599704 A 19970204 US 1995-435350 19950505
US 5817796 A 19981006 US 1995-435628 19950505
US 5801158 A 19980901 US 1996-777918 19961223
AU 9851819 A1 19980611 AU 1998-51819 19980112
AU 729657 B2 20010208
AU 9867085 A1 19980827 AU 1998-67085 19980519
AU 730506 B2 20010308
AU 9939188 A1 19990916 AU 1999-39188 19990713
AU 769175 B2 20040115 AU 2000-56616 20000911
US 2003162264 A1 20030828 US 2002-325403 20021223
US 2004033568 A9 20040219
US 2003186923 A1 20031002 US 2003-438683 20030515
ABSTRACT:
An enzymic RNA mol. is presented which specifically cleaves mRNA encoded by an mdr-1 gene, or assocd. with development or maintenance of chronic myelogenous leukemia, promyelocytic leukemia, Burkitt's lymphoma or acute lymphocytic leukemia, follicular lymphoma, B-cell acute lymphocytic leukemia, breast cancer, colon carcinoma, neuroblastoma, and lung cancer. These cancers are treated by administering the enzymic RNA. The enzymic RNA cleaves target mRNA having sequences presented. A hammerhead ribozyme was synthesized and its stability was tested in Vero and HeLa cell fractions. Liposomes contg. 15 ribozymes were prepd. and incubated with cells.
Updated 5/10/2007 1:16:18 PM
